romidepsin

Contraindicated in:

OB: Pregnancy;
Lactation: Lactation.

Use Cautiously in:

Congenital long QT syndrome, history of significant cardiovascular disease, concurrent antiarrhythmics or other medications that cause significant QT interval prolongation (↑ risk of arrhythmias);
Electrolyte abnormalities (correct magnesium and potassium abnormalities prior to use);
Moderate or severe hepatic impairment (↓ dose);
End-stage renal disease;
Pedi: Safety and effectiveness not established in children;
Geri: Older adults may be more sensitive to drug effects.

Adv. Reactions/Side Effects ⬆ ⬇

CV: ECG changes, QT interval prolongation

GI: anorexia, nausea, vomiting

Hemat: leukopenia, thrombocytopenia, ANEMIA

Neuro: fatigue

Misc: INFECTION , tumor lysis syndrome

Interactions ⬆ ⬇

Drug-drug:

May ↑ risk of bleeding withwarfarin or NSAIDs.
May ↓ effectiveness of estrogen-containing contraceptives (competes with β-estradiol for binding to estrogen receptors).
Strong CYP3A4 inhibitors, including ketoconazole, itraconazole, clarithromycin, atazanavir, nefazodone, nelfinavir, ritonavir, and voriconazole, may ↑ levels and risk of toxicity; avoid concurrent use.
Rifampin may ↑ levels and risk of toxicity; avoid concurrent use.
Strong CYP3A4 inducers, including dexamethasone, carbamazepine, phenytoin, rifabutin, rifapentine, and phenobarbital, may ↓ levels and effectiveness; avoid concurrent use.
Drugs that inhibit P-glycoprotein , including amiodarone, atorvastatin, cyclosporine, dipyridamole, ketoconazole, nelfinavir, quinidine, quinine, spironolactone, tacrolimus, and verapamil, may ↑ levels and the risk of toxicity; use cautiously.

Availability ⬆ ⬇

(Generic available)

Lyophilized powder for injection: 10 mg/vial (contains povidone; enclosed diluent contains propylene glycol and dehydrated alcohol)
Solution for injection: 5 mg/mL

Route/Dosage ⬆ ⬇

IV (Adults ): 14 mg/m² on Days 1, 8, and 15 of a 28-day cycle; cycle may be repeated every 28 days depending on benefit and patient tolerance.

Hepatic Impairment

IV (Adults ): Moderate hepatic impairment (bilirubin levels 1.5–3 times upper limit of normal [ULN]): 7 mg/m² on Days 1, 8, and 15 of a 28-day cycle; cycle may be repeated every 28 days depending on benefit and patient tolerance; Severe hepatic impairment (bilirubin levels >3 times ULN): 5 mg/m² on Days 1, 8, and 15 of a 28-day cycle; cycle may be repeated every 28 days depending on benefit and patient tolerance.

US Brand Names ⬆ ⬇

Action ⬆ ⬇

Acts as an inhibitor of histone deacetylase, which normally modulate gene expression and transcription factors. Inhibition results in cell cycle arrest and apoptosis.

Therapeutic effects:

↓extent and spread of cutaneous T-cell lymphoma.

Classifications ⬆ ⬇

Therapeutic Classification: antineoplastics

Pharmacologic Classification: enzyme inhibitors

Pharmacokinetics ⬆ ⬇

Absorption: IV administration results in complete bioavailability.

Distribution: Unknown.

Protein Binding: 92–94%.

Metabolism/Excretion: Extensively metabolized by the liver, mostly by the CYP3A4 isoenzyme.

Half-Life: 3 hr.

Time/Action Profile ⬆ ⬇

(response)

ROUTE	ONSET	PEAK	DURATION
IV	2 mo	4–6 mo	25–33 mo

Patient/Family Teaching ⬆ ⬇

Advise patient to read the Patient Information that comes with medication prior to each dose.
Instruct patient to notify health care professional promptly if excessive nausea or vomiting; abnormal heartbeat; chest pain; shortness of breath; fever; sore throat; signs of infection (burning with urination, cough, flu-like symptoms, muscle aches with or without chest pain, worsening skin problems); bleeding gums; bruising; petechiae; blood in stools, urine, or emesis; or ↑ fatigue occurs. Caution patient to avoid crowds and persons with known infections. Infection may occur during and for up to 30 days following therapy. Instruct patient to use soft toothbrush and electric razor and to avoid falls. Caution patient not to drink alcoholic beverages or take medication containing aspirin or NSAIDs, because these may precipitate gastric bleeding.
Instruct patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and consult health care professional before taking any new medications.
Rep: May cause fetal harm. Advise females of reproductive potential and males with female partners of reproductive potential to use effective nonhormonal contraception during therapy and for at least 1 mo after last dose and to avoid breastfeeding during and for at least 1 wk after last dose. Romidepsin decreases effectiveness of estrogen-containing contraceptives. Advise patient to notify health care professional if pregnancy is suspected. May impair male and female fertility.
Emphasize the need for periodic lab tests to monitor for side effects.

Pronunciation ⬆ ⬇

Code ⬆

NDC Code

0069- PFIZER LABORATORIES DIV PFIZER INC
- 0069-0983- Romidepsin
  - 0069-0983-01- 1 KIT in 1 CARTON (0069-0983-01) * 2 mL in 1 VIAL, GLASS (0069-0972-01) * 2 mL in 1 VIAL, GLASS (0069-0961-01)

0703- Teva Parenteral Medicines, Inc.
- 0703-3125- Romidepsin
  - 0703-3125-08- 1 KIT in 1 CARTON (0703-3125-08) * 2 mL in 1 VIAL, GLASS * 2 mL in 1 VIAL, GLASS

59572- Celgene Corporation
- 59572-984- ISTODAX
  - 59572-984-01- 1 KIT in 1 CARTON (59572-984-01) * 2.4 mL in 1 VIAL, GLASS (59572-973-02) * 2.2 mL in 1 VIAL, GLASS (59572-962-10)

section name header

Indications ⬇

Contraind./Precautions ⬆ ⬇